SLC5A2 and chronic kidney disease: Early detection of CKD is recommended to address cardiovascular risk, slow CKD progression, and reduce those developing ESKD.7 This can be achieved through blood pressure control, renin-angiotensin system (RAS) inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors, which have been shown to prevent adverse cardiovascular and kidney outcomes in people with CKD.8,9